Future challenges for clinical care of an ageing population infected with HIV: A modelling study

The Lancet Infectious Diseases

Volumn 15, Issue 7, 2015, Pages 810-818

  Smit, Mikaela ^a   Brinkman, Kees ^b   Geerlings, Suzanne ^c   Smit, Colette ^d   Thyagarajan, Kalyani ^e   van Sighem, Ard ^d   de Wolf, Frank ^a   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

^e University London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALENDRONIC ACID; AMLODIPINE; ATAZANAVIR PLUS RITONAVIR; ATENOLOL; BUMETANIDE; CALCIUM; CAPTOPRIL; EFAVIRENZ; EMTRICITABINE; ENALAPRIL; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; INSULIN; LAMIVUDINE; LISINOPRIL; LOPINAVIR; METFORMIN; METOPROLOL; NIFEDIPINE; PRAVASTATIN; RILPIVIRINE; TENOFOVIR; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL; VITAMIN D; ANTIRETROVIRUS AGENT;

AGING; ANTIVIRAL THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG INTERACTION; FUTUROLOGY; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEN WHO HAVE SEX WITH MEN; MORTALITY; NEOPLASM; NETHERLANDS; NON COMMUNICABLE DISEASE; OSTEOPOROSIS; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIMULATION; ADULT; AGE; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; FEMALE; HEALTH SERVICE; HIV INFECTIONS; MALE; MIDDLE AGED; NEOPLASMS; POPULATION DYNAMICS; RENAL INSUFFICIENCY, CHRONIC; THEORETICAL MODEL; TRENDS;

ADULT; AGE FACTORS; AGING; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; DRUG INTERACTIONS; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASMS; NETHERLANDS; OSTEOPOROSIS; POLYPHARMACY; POPULATION DYNAMICS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84937522755     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00056-0     Document Type: Article

References (42)

1. Smit M, Smit C, Geerlings S, et al. Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands. PLoS One 2013, 8:e76071.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-1730.
3. Gebo KA Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health 2008, 4:615-627.
4. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012, 26(suppl 1):S39-S53.
5. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011, 53:1120-1126.
6. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV Cohort Study. Clin Infect Dis 2014, 59:1787-1797.
7. Althoff KN, McGinnis KA, Wyatt CM, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected vs uninfected adults. Clin Infect Dis 2014, 60:627-638.
8. Freiberg MS, Chang C-CH, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013, 173:614-622.
9. Triant VA, Lee H, Hadigan C, Grinspoon SK Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007, 92:2506-2512.
10. Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007, 45:103-110.
11. Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection. Arch Intern Med 2007, 167:2213-2219.
12. Triant VA, Brown TT, Lee H, Grinspoon SK Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008, 93:3499-3504.
13. Brown TT, Qaqish RB Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174.
14. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197:1133-1144.
15. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008, 13:177-187.
16. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015, 29:463-471.
17. Van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003, 17:2227-2236.
18. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Fraser C 27 years of the HIV epidemic amongst men having sex with men in the Netherlands: an in depth mathematical model-based analysis. Epidemics 2010, 2:66-79.
19. Monitoring Report 2014 SHM, (accessed March 5, 2014). http://www.hiv-monitoring.nl/english/research/monitoringrapporten/.
20. Global Report UNAIDS, (accessed Feb 14, 2015). http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf.
21. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010, 24:1537-1548.
22. Guidelines European AIDS Clinical Society, (accessed Aug 4, 2014). http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
23. Appendix to Monitoring Report 2010 SHM, (accessed Nov 15, 2013). http://www.hiv-monitoring.nl/english/research/monitoringrapporten/.
24. Worm SW, Sabin CA, Reiss P, et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009, 32:474-480.
25. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010, 24:1667-1678.
26. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300:51-59.
27. Justice AC, Braithwaite RS Lessons learned from the first wave of aging with HIV. AIDS 2012, 26(suppl 1):S11-S18.
28. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 1999 2012, 60(suppl 1):S1-18.
29. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014, 67:52-58.
30. Jansson J, Wilson DP Projected demographic profile of people living with HIV in Australia: planning for an older generation. PLoS One 2012, 7:e38334.
31. Cysique LA, Bain MP, Brew BJ, Murray JM The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future. Sex Health 2011, 8:541-550.
32. Hontelez JAC, de Vlas SJ, Baltussen R, et al. The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS 2012, 26(suppl 1):S19-S30.
33. Rabkin M, Kruk ME, El-Sadr WM HIV, aging and continuity care: strengthening health systems to support services for noncommunicable diseases in low-income countries. AIDS 2012, 26(suppl 1):S77-S83.
34. Aikins A de-G, Unwin N, Agyemang C, Allotey P, Campbell C, Arhinful D Tackling Africa's chronic disease burden: from the local to the global. Global Health 2010, 6:5.
35. Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis 2010, 19:1401-1408.
36. DeStefano AL, Lew MF, Golbe LI, et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD Study. Am J Hum Genet 2002, 70:1089-1095.
37. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L Depression in HIV infected patients: a review. Curr Psychiatry Rep 2015, 17:530.
38. Watkins C, Treisman G Cognitive impairment in patients with AIDS-prevalence and severity. HIV AIDS (Auckl) 2015, 7:35-47.
39. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
40. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426.
41. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179-1193.
42. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011, 203:1791-1801.